Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      The "Missing Link" in Hematopoietic Stem Cell Transplantation

      September 26, 2016
      By Mary E. DiLorenzo, MSN, RN-C, NP-C
      Article
      Conferences|Palliative Care In Oncology Symposium

      As clinical providers, the ability to meet the science of medicine with its physical, emotional, spiritual, and financial impact it has on patients is often unintentionally overlooked or, at the very least, minimized during the active treatment phase of care; therefore, the purpose and potential benefits that result from integrating palliative care early on in the process is missed.

      Mary E. DiLorenzo, MSN, RN-C, NP-C

      Mary E. DiLorenzo, MSN, RN-C, NP-C

      Mary E. DiLorenzo, MSN, RN-C, NP-C

      As clinical providers, the ability to meet the science of medicine with its physical, emotional, spiritual, and financial impact it has on patients is often unintentionally overlooked or, at the very least, minimized during the active treatment phase of care; therefore, the purpose and potential benefits that result from integrating palliative care early on in the process is missed.

      According to a randomized control study led by Areej El-Jawahri, MD, of Massachusetts General Hospital Cancer Center in Boston, 160 patients with hematologic malignancies admitted for autologous or allogeneic HCT noted improvement in quality of life as evidenced by increased understanding of illness, lower rates of depression, anxiety, and symptom burden during hospitalization as a result of receiving palliative care services.

      Logically, the next question becomes why haven’t we been more proactive in setting into motion these services, which seemingly only benefit this patient population? In my opinion, it is the historical stigma that surrounds “palliative care” that detracts both providers from implementing it early on in the care plan as well as patients from embracing the resources inherently connected to it.

      Palliative care is wrongly thought of as only “end of life” care and consequently often implemented as such. As the ability to transplant older patients with higher risk comorbidities continues to grow, we need to acknowledge that the net result is a patient population with greater needs both emotionally and financially. What happens to the 70-year-old man who has limited financial means because he is not actively working, and then is forced to cope with chronic graft-vs-host disease—an all-too-common and potentially debilitating complication associated with allogeneic stem cell transplantation? It is this scenario, as well as a multitude of others, that must empower providers to truly understand what palliative care is, what it does, who it can benefit, and how to convey it to their patients in an appropriate and timely fashion so that the patient is willing to accept the services that palliative care can provide for them.

      This discussion would be remiss if we did not acknowledge, however, that the “end of life” aspect of palliative care does exist, and it, too, is often not discussed until a patient is actively passing or in the immediate days prior to his or her death. Thus, neither the patient nor the patient’s family members truly benefit from the variety of services available to them. Once again, it is the responsibility of the provider and healthcare team to become knowledgeable and comfortable speaking about what is truly important—the quality of life of the patient and how best to optimize it.

      The emotional and physical “roller coaster ride” that each of our patients embarks on as they undergo hematopoietic stem cell transplants should automatically guarantee them a holistic care approach of medicine that includes the input and expertise of physicians, nurses, mental health experts, social workers, allied health professionals, and ancillary services—all working in partnership as a palliative care team. It is there that the “missing link” in the care provided for these patients is found.

      Mary E. DiLorenzo, MSN, RN-C, NP-C, is an advanced practice nurse in the Blood and Marrow Transplantation Program at John Theurer Cancer Center in Hackensack, New Jersey.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Photo of a woman with shoulder-length brown hair with a maroon shirt and black blazer
      Related Content

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 12th 2025
      Article

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      September 12th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 12th 2025
      Article

      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      September 12th 2025
      Podcast

      Image of bone marrow with cancer cells

      Venetoclax Combo Did Not Increase OS in Intermediate/High-Risk MDS

      Ariana Pelosci
      September 12th 2025
      Article

      Photo of a woman with blond hair wearing a white and black blazer

      How to Manage ICANS in Patients With Hematologic Cancers

      Gina Mauro
      September 12th 2025
      Article
      Related Content

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 12th 2025
      Article

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      September 12th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 12th 2025
      Article

      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      September 12th 2025
      Podcast

      Image of bone marrow with cancer cells

      Venetoclax Combo Did Not Increase OS in Intermediate/High-Risk MDS

      Ariana Pelosci
      September 12th 2025
      Article

      Photo of a woman with blond hair wearing a white and black blazer

      How to Manage ICANS in Patients With Hematologic Cancers

      Gina Mauro
      September 12th 2025
      Article

      Latest Conference Coverage

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

      Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.